Earum Pharmaceuticals Share Price

CMP as on20-May-22 15:33

₹ 5.21
0.07 1.36%

Open

₹ 5.26

Turnover (lac)

₹ 305

Prev. Close

₹ 5.14

Day's Vol (shares)

₹ 1,85,643

Day's Range

₹ 5.12
₹ 5.26

Corporate Action

Go
Purpose AGM Date Announcement Date Book Closure Start Date Book Closure End Date
Board Meeting - 11-Apr-2022 - -
Earum Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 18/04/2022 ,inter alia, to consider and approve Intimation of Board Meeting Outcome of Board Meeting held on April 18,2022 (As Per BSE Announcement Dated on 18.04.2022)
Board Meeting - 12-Feb-2022 - -
Intimation under Regulation 30 read with Schedule III of the SEBI (LODR) Regulation, 2015 - Consent given to Mr. Bhumishth N. Patel [DIN: 02516641], Chairman and Managing Director of the Company, to become Managing Director in EVOQ Remedies Limited
Board Meeting - 03-Feb-2022 - -
Outcome of Board Meeting held on February 03,2022 Appointment of Secretarial Auditor
Board Meeting - 01-Jan-2022 - -
Earum Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/01/2022 inter alia to consider and approve Intimation of Board Meeting to be held on January 082022 Quarterly Results (Revised) (As per BSE Bulletin Dated on 07/01/2022) Earum Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/01/2022 ,inter alia, to consider and approve Postponement of Board Meeting (As per BSE Announcement Dated on 07/01/2022) Outcome of Board Meeting held on January 11, 2022 , to consider quarterly and nine months ended financial results (As Per BSe Announcement Dated 11.01.2022)
Board Meeting - 21-Oct-2021 - -
Quarterly Results Earum Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/10/2021 ,inter alia, to consider and approve Intimation of Board Meeting to be held on October 30,2021 Considered and approved Unaudited financial results for the quarter and half year ended on September 30,2021 (As per BSE Announcement Dated on 30/10/2021)
Board Meeting - 23-Sep-2021 - -
Stock Split Board to consider sub-division/stock split Revised outcome Outcome of Board Meeting held on October 08,2021 Board approves split of shares of the Company (As Per BSE Announcement Dated on 10/8/2021 6:08:58 AM)
Board Meeting - 07-Sep-2021 - -
Outcome of Board Meeting held on September 07,2021
Board Meeting - 31-Jul-2021 - -
Earum Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2021 ,inter alia, to consider and approve Dear Sir/Madam, Pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the meeting of Board of Directors of our Company is scheduled to be held on Wednesday, August 11, 2021 at the Corporate Office of the Company to transact the following businesses: 1. To consider and allot the Bonus Equity Shares of Rs. 10/- each in a ratio of Rs. 1:1 i.e. One Equity Shares of Rs. 10/- each for every One Equity Shares of Rs. 10/- each to the member eligible for such allotment as on Record Date i.e. August 10,2021 2. Any other business with the permission of Chair Kindly take the note of the same and oblige. Thanking You. Outcome of Board Meeting held on 11.08.2021 Announcement under Regulation 30 (LODR)- Bonus Allotment (As Per BSE Announcement Dated on 11.08.2021)
Board Meeting - 27-Jul-2021 - -
Earum Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/08/2021 ,inter alia, to consider and approve To consider and approve the revised audited Standalone Financial Results of the Company for the half year and year ended on March 31, 2021 Outcome Of Board Meeting Held On August 02, 2021 And Submission Of Revised Audited Financial Results For The Financial Year Ended 31st March, 2021 Pursuant To Regulation 33 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015. (As per BSE Announcement Dated on 2/8/2021)
Board Meeting - 13-Jul-2021 - -
Earum Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/07/2021 ,inter alia, to consider and approve Dear Sir/Madam, We hereby inform you that, pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, a meeting of the Board of Directors of the Company will be held on Wednesday, 21st July, 2021 at the Corporate Office of the Company Situated At A-1106, Empire Business Hub, Near Auda Water Tank, Science City Road, Sola, Ahmedabad, Gujarat - 380060, inter alia to transact the following business: 1. To Consider Migration from SME Platform of BSE to the Main Board of NSE 2. Any other business with the permission of the Chair This is for your information and record. Thank you. Outcome of Board Meeting held on 21.07.2021 Appointment of Secretarial Auditor (As Per BSE Announcement dated on 21.07.2021)
Board Meeting - 29-May-2021 - -
Earum Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/06/2021 ,inter alia, to consider and approve We hereby inform you that, pursuant to Regulation 29 of the securities and Exchange board of India (Listing obligations and disclosures Requirements) Regulations, 2015, a meeting of the Board of Directors of the company scheduled to be held on Thursday, 10th June, 2021 at 04:00 PM at the Corporate Office Of The Company Situated At A-1106, Empire Business Hub, Near Auda Water Tank, Science City Road, Sola, Ahmedabad, Gujarat - 380060, inter alia to transact the following business: 1. To consider and approve Increase in Authorised Share Capital of the Company. 2. To consider and approve the Issue of Bonus Shares. 3. To appoint Mr. Dahyabhai Mafatlal Patel as Additional Director of the Company. 4. Approval of Audited Financial Results of the Company for the quarter and financial year ended on March 31, 2021. 5. To consider an issuance of equity shares to the directors of the company on preferential basis against the conversion of unsecured loans lying in the company from directors.
Board Meeting - 31-May-2021 - -
Earum Pharmaceuticals Ltd has informed BSE that a meeting of the Board of Directors of the Company scheduled to be held on June 10, 2021, inter alia, to transact the following business: 1. To consider and approve Increase in Authorised Share Capital of the Company. 2. To consider and approve the Issue of Bonus Shares. 3. To appoint Mr. Dahyabhai Mafatlal Patel as Additional Director of the Company. 4. Approval of Audited Financial Results of the Company for the quarter and financial year ended on March 31, 2021. 5. To consider an issuance of equity shares to the directors of the Company on preferential basis against the conversion of unsecured loans lying in the Company from directors. Further, as per the Companys code of conduct to regulate, monitor and report trading by insiders, adopted by the Board pursuant to SEBI (Prohibition of insider trading) Regulations, 2015, the trading window for dealing in the securities of the Company by the designated persons and their immediate relatives of the Company has already been closed from April 01, 2021 and shall remain closed till 48 hours from the closure of the Board Meeting. Earum Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on June 10, 2021, inter alia, have approved and recommended the issuance of fully paid up bonus shares in the ratio of 1:1 (i.e. 1 fully paid up share for every 1 fully paid up equity shares held, subject to the shareholders approval through postal ballot. 1. increase in authorised share capital of the company from existing Rs. 7,00,00,000 (Rupees Seven Crore) divided into 70,00,000 (Seventy Lakh) equity shares of Rs. 10/- each to Rs.12,35,00,000 (Rupees Twelve Crore Thirty Five Lakh) 2. issuance of fully paid up bonus shares in the ratio of 1:1 3. appoint Mr. Dahyabhai Mafatlal Patel as an additional director 4. 4. The Board approve the Audited financial results of the company for the financial year ended on 31st March, 2021 5. issuance of equity shares to the directors of the company on preferential basis against conversion of unsecured loans 6. Migration of company from BSE SME platform to Main board of BSE Limited 7. Appointment of M/s Shikha Patel & Associates, PCS as the scrutiniser for postal ballot process (As Per BSE Announcement Dated on 10.06.2021)
Open ZERO Brokerage Demat Account Open Demat Account

  • 0

    Per Order for ETF & Mutual Funds Brokerage

  • 20

    Per Order for Delivery, Intraday, F&O, Currency & Commodity